Does comorbidity explain trends in prescribing of newer antihypertensive agents?

Journal of Hypertension

Volumn 22, Issue 11, 2004, Pages 2209-2215

  Greving, Jacoba P ^a   Denig, Petra ^a   Van Der Veen, Willem Jan ^a   Beltman, Frank W ^a   Sturkenboom, Miriam C J M ^b   De Zeeuw, Dick ^a   Haaijer Ruskamp, Flora M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antihypertensive agents; Comorbidity; Drug utilization review; Evidence based medicine; Hypertension; Primary health care

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; ASTHMA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 7744241958     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200411000-00025     Document Type: Article

References (31)

1. Moser M. Results of the ALLHAT trial: is the debate about initial antihypertensive drug therapy over? J Clin Hypertens 2003; 5:5-8.
2. Frohlich ED. Treating hypertension - what are we to believe? W Engl J Med 2003; 348:639-641.
3. Walma EP, Grundmeijer HGLM, Thomas S, Prins A, Van den Hoogen JPH, van der Laan JR. The standard on hypertension of the Dutch Society of general practitioners. Huisarts Wet 1997; 40:598-617.
4. Grobbee DE, Tuut MK, Hoes AW. CBO guideline 'high blood pressure' (revision). Ned Tijdschr Geneeskd 2001; 145:2071-2076.
5. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancer 1999; 353:611-616.
7. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
10. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995; 155:829-837.
11. Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens 1998; 16:1545-1553.
12. Knight EL, Glynn RJ, Levin R, Ganz DA, Avorn J. Failure of evidence-based medicine in the treatment of hypertension in older patients. J Gen Intern Med 2000; 15:702-709.
13. Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension. Arch Intern Med 2001; 161:1873-1879.
14. Onder G, Gambassi G, Landi F, Pedone C, Cesari M, Carbonin PU, et al. Trends in antihypertensive drugs in the elderly: the decline of thiazides. J Hum Hypertens 2001; 15:291-297.
15. Bog-Hansen E, Lindblad U, Ranstam J, Melander A, Rastam L. Antihyper tensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project. Pharmacoepidemiol Drug Saf 2002; 11:45-54.
16. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
17. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macro-vascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
19. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens 1999; 12:333-340.
20. Clause SL, Hamilton RA. Medicaid prescriber compliance with Joint National Committee VI Hypertension Treatment Guidelines. Ann Pharmacother 2002; 36:1505-1511.
21. Weiss R, Buckley K, Clifford T. Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000. Clin Ther 2002; 24:1451-1462.
22. World Organization of Family Doctors (WONCA). ICPC-2 International classification of primary care. New York: Oxford University Press; 1998.
23. WHO Collaboration Centre for Drug Statistics Methodology. ATC index with DDDs 1999. Oslo: WHO; 1999.
24. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Meth Inf Med 1999; 38:339-344.
25. Ribacke M. Treatment preferences, return visit planning and factors affecting hypertension practice amongst general practitioners and internal medicine specialists (the General Practitioner Hypertension Practice Study). J Intern Med 1995; 237:473-478.
26. GIPeilingen 1996-2000. Kengetallen Farmaceutische Hulp nr. 18. Amstelveen: GIP/Health Care Insurance Board; 2002.
27. IMS Health. National Prescription Audit. Dispensed antihypertensive drugs 1997-2002. The Hague: IMS Health; 2002.
28. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
29. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003; 123:222-243.
30. de Vries CS, van Diepen NM, Tromp TF, de Jong-van den Berg LT. Auditing GPs' prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. Eur J Clin Pharmacol 1996; 50:349-352.
31. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001; 323:378-381.